The U.S. FDA granted breakthrough therapy designation to Abbisko Therapeutics Co. Ltd.’s colony-stimulating factor 1 receptor (CSF-1R) inhibitor, pimicotinib, for patients with tenosynovial giant cell tumors who are not able to have surgery.
Winning the race to market with the first oral selective estrogen receptor degrader (SERD) for breast cancer is Menarini Group’s elacestrant, which gained U.S. FDA approval for use as second- and third-line therapy in patients with ER-positive/HER2-negative advanced or metastatic disease with the ESR1 mutation. It marks the first therapy approved specifically targeting ESR1, found in up to 40% of patients with ER-positive/HER2-negative disease.
TYK Medicines Inc. and Zhejiang Tongyuankang Pharmaceutical Co. Ltd. have identified tyrosine-protein phosphatase non-receptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of cancer and LEOPARD and Noonan syndrome.
Dana-Farber Cancer Institute Inc. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to an anaplastic lymphoma kinase (ALK)-targeting moiety through a linker reported to be useful for the treatment of cancer.
Mantle cell lymphoma (MCL) patients developing resistance to existing BTK inhibitors now have a new treatment option, with the U.S. FDA’s accelerated approval of Jaypirca (pirtobrutinib) from Eli Lilly and Co.’s oncology unit, Loxo@Lilly. It is indicated for use in adults with relapsed or refractory disease who have received at least two lines of systemic therapy, including a BTK inhibitor.
Caribou Biosciences Inc.’s disclosure last December that it has chosen the target for CB-020, an induced pluripotent stem cell-derived allogeneic CAR-NK cell therapy for solid tumors, added impetus to the growing interest in receptor tyrosine kinase-like orphan receptor 1 (ROR1), where a number of parties are advancing programs.
Androgen deprivation therapy (ADT) is still the main treatment option for locally advanced and metastatic prostate cancer (PCa); however, most patients receiving ADT develop resistance to treatment and relapse, with a more aggressive form of cancer, castration-resistant prostate cancer (CRPC).
Centessa Pharmaceuticals plc has received clearance of its IND application from the FDA to initiate a first-in-human phase I/IIa trial of LB-101 for the treatment of solid tumors.
RSS
